CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.3 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02049411
NCT02049411Phase 2Completed

Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.

Instituto Mexicano del Seguro Social·interventional·Posted Jan 30, 2014·Updated Nov 25, 2014

In Brief

A Phase 2 clinical trial evaluating Ketamine and physiological solution for Postoperative Cognitive Dysfunction. Completed, enrolled 80 participants across 1 site.

Detailed Summary

\- Cognitive changes are related to aging, affecting the performance of older patients in the solution of problems and the execution of tasks. This phenomenon has been observed as a decline of neurophysiological domains, especially memory, and the velocity of thought. * Anesthesia and surgery performed contributes to its development then, is named post-operative cognitive dysfunction (POCD). The incidence varies due to conditions of: 1. Anesthesia and surgery. 2. The time elapsed after surgery. 3. The population studied, and the type of cognitive test employed. * The aim of this study is to evaluate the changes around the Short Portable Mental Status Questionnaire (SPMSQ-E) after ketamine administration on ophthalmic surgery on the common conditions of geriatric patients, -comorbid and settings as minor surgery-.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 30, 2014
Enrollment StartJun 1, 2013
Primary CompletionJan 1, 2014
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.4 years ago

Interventions

Ketaminedrug

Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.

physiological solutiondrug

physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.